No Data
Emerging Markets outlook: The Growth Market 250 Index ETF failed to break through the 200-day moving average, and the market may continue to lack direction.
■Weak movements due to expectations of a policy interest rate hike; this week, Emerging Markets declined. During the same period, the Nikkei Average fell by -1.89%, while the Growth Market Index dropped by -2.75% and the Growth Market 250 Index decreased by -2.93%, showing weakness compared to the Nikkei Average. The Growth Market 250 Index was expected to break through the resistance of the 200-day moving average (200MA), but it failed, worsening investor sentiment. Trading volume showed no significant changes, remaining in the 100 billion yen range, as the policy interest rate was influenced by the Bank of Japan.
Stocks with peculiar taste from volume change, such as Modaris, etc.
Closing price of stocks compared to the previous day, Volume * <7371> Zenken 5,062,298,000 * <4736> Japan Rad 860,150,448,000 * <3858> Ubi AI 497,742,828,500 * <4883> Modalis 109,728,896,000 * <4885> Muromachi Chemical 981,503,002,00 * <9439> MH Group 1,952,143,900 * <4893> Noile Immun 182,121,460,600 * <9204> Skymark 602,372,521.
Noil Immune Biotech --- Selection of loan stocks in the Tokyo Stock Exchange Growth Market.
Noil Immune Biotech <4893> announced on the 20th that it has been selected as a borrowable stock in the Tokyo Stock Exchange's Growth Market. The company is an academia-origin biotech firm working on the practical application of next-generation cancer immunotherapy for solid tumors using its unique innovative technology, "PRIME technology," which enhances the therapeutic effects of immune cell therapy through PRIME CAR-T cells. The selection date is December 23, 2024 (Monday), and the implementation will start from the trading of that day.
Noil Immune, True Data, among others.
Revised financial estimates: forecasted consolidated ordinary profit for the first half is 0.013 billion yen, down from 0.027 billion yen, and the full-year consolidated ordinary profit forecast is 0.101 billion yen, down from 0.136 billion yen.
Noile-Immune Biotech: Notice regarding publication of earnings forecasts
Noile-Immune Biotech: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)